Insider transactions

EDGAR

ACURX PHARMACEUTICALS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–8 of 8

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-04-20 Filed 2026-04-22DELUCCIA ROBERT J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (37,100) — exercise price 2.36
Acquired (A)37,1000—37,100Direct (D) No
F1
  • F1 On April 20, 2026 (the Grant Date), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
Open filing 0001104659-26-046836 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22HARRISON THOMAS L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (2,150) — exercise price 2.36
Acquired (A)2,1500—2,150Direct (D) No
F1
  • F1 This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.
Open filing 0001104659-26-046840 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22LUCI DAVID P Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (37,100) — exercise price 2.36
Acquired (A)37,1000—37,100Direct (D) No
F1
  • F1 On April 20, 2026 (the Grant Date), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
Open filing 0001104659-26-046835 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Donohue James J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (2,150) — exercise price 2.36
Acquired (A)2,1500—2,150Direct (D) No
F1
  • F1 This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.
Open filing 0001104659-26-046842 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Sailer Carl Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (2,150) — exercise price 2.36
Acquired (A)2,1500—2,150Direct (D) No
F1
  • F1 This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.
Open filing 0001104659-26-046846 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Shawah Robert G. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (25,900) — exercise price 2.36
Acquired (A)25,9000—25,900Direct (D) No
F1
  • F1 On April 20, 2026 (the Grant Date), the Reporting Person was granted stock options to purchase 25,900 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
Open filing 0001104659-26-046833 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Scodari Joseph C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (2,150) — exercise price 2.36
Acquired (A)2,1500—2,150Direct (D) No
F1
  • F1 This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.
Open filing 0001104659-26-046837 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22DEAN JACK H Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (2,150) — exercise price 2.36
Acquired (A)2,1500—2,150Direct (D) No
F1
  • F1 This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.
Open filing 0001104659-26-046844 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Armistice Capital, LLC Common Stock4.9983,233.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001172661-25-005168 Dispute this row
Steven Boyd Common Stock4.9983,233.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001172661-25-005168 Dispute this row
Armistice Capital, LLC Common Stock8.702,917,975.0006/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001172661-25-003563 Dispute this row
Steven Boyd Common Stock8.702,917,975.0006/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001172661-25-003563 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,686,506 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015103,592
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,124

Filings made before the SEC required XML are listed, not extracted.

Back to ACURX PHARMACEUTICALS, INC.